Baicalin nanoemulsion mitigates cisplatin-induced hepatotoxicity by alleviating oxidative stress, inflammation, and restoring cellular integrity.

Abstract

Cisplatin is a widely used chemotherapeutic agent, but its clinical utility is limited by side effects affecting different systems and organs, including hepatotoxicity in some cases. Baicalin, a flavonoid isolated from Scutellaria baicalensis, possesses antioxidant, anti-inflammatory and hepatoprotective properties, but its low bioavailability limits its therapeutic use. This study aimed to investigate whether a nanoemulsion formulation of baicalin could enhance its efficacy against cisplatin-induced hepatic injury in rats. Rats were orally treated daily with baicalin either in nanoformulation (10 or 20 mg/kg body weight per day) or conventional form (100 mg/kg body weight per day) for 12 days. Cisplatin (10 mg/kg body weight) was injected intraperitoneally on day six and day twelve to induce hepatic injury. Samples were collected on day thirteen. Serum markers, oxidative stress parameters, inflammatory markers, cellular energy status, histopathology, and other endpoints were evaluated. Results revealed that cisplatin caused elevated serum enzymes, oxidative stress, inflammation, DNA damage, depleted cellular energy levels, and induced severe hepatic histological changes. The baicalin nanoemulsion especially the higher 20 mg/kg dose, significantly ameliorated cisplatin-induced abnormalities across the various parameters. The conventional baicalin suspension also provided protection, albeit to a lesser degree than the nanoemulsion. In conclusion, administering baicalin as a nanoemulsion potentiated its hepatoprotective effects against cisplatin toxicity. The nanoemulsion formulation strategy was proven promising for enhancing baicalin's therapeutic utility.